Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The wet macular degeneration market attained a value of USD 10.09 Billion in 2025, driven by the rising aging population and advancements in treatment options across the 8 major markets. It is expected to grow at a CAGR of 5.90% in the forecast period of 2026-2035, and attain a value of USD 17.90 Billion by 2035.
Q1 2026 Market Updates
Geopolitical Impact of Iran, US, and Israel War on the Wet Macular Degeneration Market
United States: The Wet Macular Degeneration Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Petrochemical-derived pharmaceutical packaging materials including blister packs, polymer bottles, and specialty film coatings are facing 15-20% cost inflation from the Gulf supply disruption. API production costs are rising as petrochemical reagent prices increase 15-20%. Air freight costs have spiked dramatically, with temperature-sensitive pharmaceutical distribution facing elevated costs and extended lead times as Gulf carrier networks remain suspended. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets. Clinical trial operations in Middle Eastern investigator sites have been disrupted, and medical supply chains face elevated logistics costs.
Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for wet macular degeneration conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.
Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for wet macular degeneration indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.
Key Takeaways
Government
- Relevant health authorities should activate emergency pharmaceutical supply chain resilience protocols, ensuring that API and packaging material sourcing for essential wet macular degeneration treatments is not concentrated in Gulf-adjacent supply chains exposed to maritime disruption.
- Regulatory agencies should fast-track review of treatment availability and consider emergency compassionate use extensions for patients in conflict-affected regions who face interruption to their standard of care.
- Governments should monitor petrochemical-derived pharmaceutical packaging cost inflation, ensuring that price increases remain within access thresholds for patients requiring ongoing wet macular degeneration treatment.
Market
- Petrochemical-derived pharmaceutical packaging and API precursor costs are rising 15-20%, creating margin compression for wet macular degeneration manufacturers in the near term, with limited ability to pass costs through in price-regulated markets.
- The conflict's disruption to clinical trial infrastructure in Middle Eastern sites may modestly delay regulatory submissions and new treatment launches that had enrolled patients from the region, though the structural market growth trajectory remains intact.
- Healthcare system demand for wet macular degeneration treatment is fundamentally driven by disease burden and demographics rather than geopolitical events, providing strong structural insulation for the market's long-term growth trajectory.
Procurement
- Pharmaceutical procurement teams should build 90-day safety stock for essential wet macular degeneration treatment drugs and biological agents, hedging against further pharmaceutical logistics cost increases and potential supply disruptions.
- API and excipient buyers should review single-source supplier risks for Gulf-adjacent petrochemical-derived pharmaceutical inputs, establishing secondary supply arrangements with non-Gulf origin manufacturers in India, China, and Europe.
- Hospital pharmacy procurement managers should review cold-chain logistics contracts for temperature-sensitive wet macular degeneration therapeutics, ensuring that alternative air routing through non-conflict-zone hubs is available if Gulf carrier services remain suspended.
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
-
Progress in anti-VEGF treatments, such as ranibizumab and aflibercept, alongside developments like gene therapies and long-acting treatments, are increasing treatment choices and driving market growth.
-
In September 2024, the FDA approved Pavblu as the fifth biosimilar referencing Eylea. The acceptance of numerous biosimilars enhances competition, leading to market expansion by enhancing accessibility and affordability of treatment.
-
The United States is expected to dominate the market, driven by its sophisticated healthcare system, large aging population, and significant investment in research and advanced treatment options.
Compound Annual Growth Rate
5.9%
Value in USD Billion
2026-2035
*this image is indicative*
Wet Macular Degeneration Market Overview
Wet macular degeneration (or neovascular AMD) is a long-term disease that affects central vision in senior citizens. Wet macular degeneration is a more serious condition and is a type of AMD marked by a severe, rapid loss of central vision in the retina where macular degeneration has occurred. This condition develops when the small blood vessels beneath the macula of the retina swarm and ooze out fluids like blood. While the rest of the retina is involved in the peripheral vision, the macula is responsible for the central vision, necessary for reading or identifying faces. Symptoms are effectively controlled by early intervention, and medications like anti-VEGF injections can delay the progression of the condition.
Wet Macular Degeneration Market Growth Drivers
Increasing Aging Population to Boost the Market Growth
In a report, the World Health Organization (WHO) highlighted that with increasing life expectancy, a large number of individuals will reach 60 or older by 2050. Wet macular degeneration cases are bound to surge with the increasing incidence of the geriatric population base, leading to increased demand for treatment among the elderly with vision-related diseases.
FDA Approval Boosts the Market Growth
In September 2024, Pavblu, the fifth biosimilar referencing Eylea (aflibercept), was approved by the FDA for the treatment of retinal conditions such as wet age-related macular degeneration. Pavblu, developed by Amgen, was approved after a phase 3 study with 576 patients from various countries. It is one of several biosimilars that got approval in 2024, along with Yesafili, Opuviz, Ahzantive, and Enzeevu. There is a growing emphasis on early detection and preventive healthcare. Increasing approvals from essential regulatory authorities is expected to boost the market value in the forecast period.
Wet Macular Degeneration Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Wet Macular Degeneration Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Stage
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
Market Breakup by Treatment Type
- Drugs
- Anti-vascular Endothelial Growth Factor
- Dietary Supplements
- Others
- Devices
- Glasses
- Contact Lenses
- Others
- Surgery
Market Breakup by Route of Administration
- Intravenous Route
- Intravitreal Route
Market Breakup by End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Wet Macular Degeneration Market Share
Market Segmentation Based on the Route of Administration Set to Witness Substantial Growth
The market is segmented into intravenous route and intravitreal route based on the route of administration. Among these, the intravitreal method is expected to dominate the market because it directly administers drugs into the eye, resulting in improved treatment results and fewer overall side effects. Medications such as Ranibizumab (Lucentis) and Aflibercept (Eylea) are often given through injections directly into the eye. This technique enables focused treatment of the retina, effectively preventing the growth of abnormal blood vessels. Due to its established efficacy and lower risks when compared to systemic delivery, intravitreal therapy continues to be considered the preferred treatment method for wet AMD.
Segmentation Based on End User Holds a Significant Market Share
The market is divided into hospitals, clinics, ambulatory surgical centers, homecare settings, and others. Among these, hospitals and clinics are expected to dominate the market because of their specialized ophthalmologists and advanced diagnostic equipment. They provide thorough treatment, which includes giving anti-VEGF medications such as Lucentis and Eylea via injections into the eye. Ambulatory surgical centers also hold a substantial share due to their affordability, while homecare settings are utilized for remote monitoring and occasional medical care.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Wet Macular Degeneration Market Analysis by Region
Based on region, the market report covers the United States, EU-4, and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. Due to advanced healthcare systems and substantial investment in research, the United States is expected to dominate the market. Factors like increasing elderly populations and lifestyle-related risks impact the market in this area. The government's backing promotes market expansion through leadership in clinical trials and innovative treatments such as targeted therapies and immunotherapies. The market is growing due to greater emphasis on early detection and personalized treatment choices.
Leading Players in the Wet Macular Degeneration Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bayer AG
Bayer AG, headquartered in Leverkusen, Germany, is a leading pharmaceutical company in the age-related wet macular degeneration (AMD) market. Their primary product, Eylea (aflibercept), is a very effective treatment for wet AMD that can preserve and even improve vision. Bayer remains committed to investing in the research and development of new AMD therapies.
F-Hoffmann La Roche Ltd.
Established in 1896 and headquartered in Basel, Switzerland. Roche specializes in ophthalmic disorder drugs. They developed Lucentis, a popular anti-VEGF therapy drug for wet AMD, through Genentech. They are working on new delivery methods and long-acting formulations to reduce reliance on frequent injections in AMD treatment, leveraging their biopharmaceutical expertise.
Pfizer Inc.
Pfizer Inc. is a significant player in the wet age-related macular degeneration (AMD) market, which is highly competitive and poised for growth due to the aging global population and the rising prevalence of eye disorders.
Novartis AG
Novartis AG is a leading player in the market, primarily through its flagship drug, Lucentis (ranibizumab), a pioneering anti-VEGF therapy developed in partnership with Genentech.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Panoptica Pharma, Bausch + Lomb, Regeneron Pharmaceuticals Inc., Ocugen Inc., REGENXBIO Inc., and Oxurion NV, among others.
Key Questions Answered in the Wet Macular Degeneration Market
- What was the wet macular degeneration market value in 2025?
- What is the wet macular degeneration market forecast outlook for 2026-2035?
- What are the regional markets covered in the EMR report?
- What is the market breakup based on the disease stage?
- What is the market segmentation based on the treatment type?
- What is the market breakup based on the route of administration?
- What major factors aid the wet macular degeneration market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major wet macular degeneration market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players in the wet macular degeneration market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- How does the management of intermediate AMD differ from late-stage AMD?
- What role do anti-VEGF drugs play in wet AMD treatment?
- Why is the intravitreal route the preferred method for wet AMD treatment?
- Why does the United States lead the wet AMD market?
- What factors drive the wet AMD market in EU-4 and the UK?
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Stage |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share